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ABSTRACT
Zipper-interacting Protein Kinase (ZIPK) belongs to the death-associated protein 
kinase family. ZIPK has been characterized as a tumor suppressor in various tumors, 
including gastric cancer. On the other hand, ZIPK also promotes cell survival. In this 
study, both in vitro and in vivo assays indicated that ZIPK promoted cell growth, 
proliferation, migration, invasion, tumor formation and metastasis in nude mice. 
ZIPK induced epithelial-mesenchymal transition (EMT) with increasing expression 
of β-catenin, mesenchymal markers, Snail and Slug, and with decreasing expression 
of E-cadherin. Furthermore, ZIPK activated the AKT/IκB/NF-κB pathway, which 
can promote EMT and metastasis. Additionally, ZIPK expression was detected in 
human primary gastric cancer and their matched metastatic lymph node samples 
by immunohistochemistry. Increased expression of ZIPK in lymph node metastases 
was significantly associated with stage VI and abdominal organ invasion. Survival 
analysis revealed that patients with increased ZIPK expression in metastatic lymph 
nodes had poor disease-specific survival. Taken together, our study reveals that ZIPK 
is a pro-oncogenic factor, which promotes cancer metastasis.
INTRODUCTION
Gastric cancer (GC) is the second most common 
cause of cancer-related death in the world and 42% 
of the cases occur in China [1]. Although the surgical 
approaches and adjuvant chemotherapy have been 
improved, the survival rate of GC patients at advanced 
stages remains low. The treatment failure may reflect the 
poorly understood biology of gastric cancer cells and their 
underlying signal transduction pathways. Accumulating 
evidence has suggested that the deregulation of cell death 
and survival pathways may promote tumor development 
and progression, with potentially devastating consequences 
for cancer patients [2]. Therefore, it is imperative to 
investigate the molecular mechanisms of gastric cancer to 
improve therapeutic approaches and patient outcomes.
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Zipper-interacting Protein Kinase (ZIPK), or DAPK3, 
belongs to the death-associated protein kinase family which 
also includes DAPK1 and DAPK2. As their name imply, the 
three kinases share significant homology within their common 
N-terminal kinase domain and share some functions such as 
caspase-dependent and -independent cell death induction. 
ZIPK colocalizes with Par4 at actin filaments to cause the 
formation of thick actin bundles and apoptotic events [3]. 
ZIPK also induces the diphosphorylation of the regulatory 
light chain of myosin II in non-muscle cells and gives rise to 
apoptotic morphological changes [4]. Moreover, ZIPK is a 
downstream target of DAPK1 and may potentiate DAPK1-
mediated apoptosis [5]. On the other hand, ZIPK has a critical 
role in the regulation of starvation -induced autophagy and 
Atg9-mediated autophagosome formation through the myosin 
II motor protein [6]. ZIPK has been linked to several cell 
death–related signaling pathways. In accordance with its cell 
death promoting activity, some evidences suggest that ZIPK 
functions as a tumor suppressor. ZIPK mRNA expression 
was reportedly decreased in skin squamous cell carcinoma 
[7]. Our previous study showed that decreased expression of 
ZIPK was detected in 111/162 primary gastric carcinomas, 
which was significantly associated with invasion, metastasis 
and poor prognosis [8]. Furthermore, somatic ZIPK mutations 
have been discovered in colon cancer, ovarian cancer and 
lung cancer. Such mutations block kinase activity and 
promote cancer cell survival [9].
However, the DAPK family exhibits anti-apoptotic 
activity under certain conditions. Silencing of DAPK by 
siRNA could result in apoptosis [10]. DAPK1 positively 
regulates mTORC1 in response to growth factor activation 
by binding to TSC2 and regulating its phosphorylation. 
The novel link between DAPK1 and mTORC1 signaling 
pathways has suggested that DAPK1 plays a pivotal role 
in cell survival [11]. Recently, ZIPK has been described 
as a novel transcriptional co-activator of androgen 
receptor (AR). ZIPK may regulate AR anti-apoptotic and 
proliferative functions and provide a growth advantage to 
prostate cancer cells [12]. Until now, the nature of ZIPK in 
gastric cancer pathogenesis is unclear. In the current study, 
we used both in vitro and in vivo assays to characterize 
ZIPK function in gastric cancer cell lines. We found that 
ZIPK activates AKT/IκB/NF-κB pathway which could 
promote cancer cell epithelial-mesenchymal transition and 
metastasis. Increased expression of ZIPK merely in human 
metastatic lymph nodes compared to the expression of 
ZIPK in their primary GCs is associated with abdominal 
organ metastases and patient’s poor survival.
RESULTS
Overexpression of ZIPK increases cell growth 
and proliferation
To characterize the biological effect of ZIPK on 
cell growth and proliferation in gastric cancer cell lines, 
ZIPK was stably transfected into BGC-823 cells (ZIPK 
clone1 or ZIPK clone2). Empty vector–transfected cells 
were used as control (Vec-BGC823). Meanwhile, ZIPK 
in SGC-7901 and SNU-1 cells were silenced by siRNAs. 
Ectopic overexpression and decreased expression of 
ZIPK were determined by RT-PCR and Western blotting 
(Supplementary Figure 1). XTT assays showed that 
ZIPK overexpression markedly increased BGC-823 cell 
proliferation. Conversely, silencing ZIPK inhibited cell 
proliferation in SGC-7901 and SNU-1 cells (P < 0.01 
Figure 1A). Anchorage-dependent foci formation and 
anchorage-independent colony formation in soft agar 
yielded a higher number and larger colonies (P < 0.01) in 
the ZIPK-transfected cells compared to the control cells 
(Figure 1B, 1C). The tumorigenic potential of ZIPK was 
also evaluated by xenograft tumor formation in athymic 
nude mice. Subcutaneous visible tumors were observed 
in the left flank (ZIPK clone1) in all 5 tested animals on 
day 7 after injection. However, visible tumor in the right 
flank (Vec-BGC823) was only observed in 2 nude mice 
on day 14. Xenograft tumor growth curve indicated that 
tumors induced by ZIPK-transfeced cells grew much more 
rapidly than tumors induced by Vec-BGC823 cells (P < 
0.001; Figure 1D). On day 28 after injection, tested mice 
were sacrificed and the tumors were excised for further 
analysis. The average volume of tumors induced by ZIPK 
clone cells (186 ± 48.8 mm3) was significantly increased 
compared with tumors induced by Vec-BGC823 cells (8.8 
± 10.5 mm3, P < 0.001; Figure 1D).
ZIPK promotes cell invasion in vitro and tumor 
metastasis in vivo
After confirming the tumorigenic ability of ZIPK, we 
investigated the roles of ZIPK in cell migration, invasion 
and tumor metastasis. Wound healing assay showed 
that ZIPK-transfected cells obtained quicker closure of 
the scratched “wound” and silencing ZIPK resulted in 
a significant delay of scratch area closure (Figure 2A). 
In addition, we further measured cell migration and 
invasion using Transwell assays in ZIPK-transfected, 
ZIPK-silenced and their respective control cells. ZIPK 
overexpression significantly increased cell migration and 
invasiveness in BGC-823 cell line. Knockdown of ZIPK 
repressed cell migration and invasion in SGC-7901 and 
SNU-1 cells (P < 0.001; Figure 2B). To evaluate the in 
vivo effects of ZIPK on tumor metastasis, two groups of 
5 mice each were injected intravenously in the tail vein 
with ZIPK-transfected cells or Vec-BGC823, respectively. 
After 8 weeks, the mice were sacrificed, and the metastatic 
nodules at the lung surfaces were counted. A significantly 
larger number of metastatic nodules were induced at 
the surface of the lungs of mice injected with the ZIPK-
transfected cells than those with the Vec-BGC823 cells 
(P < 0.001, Figure 2C). Hematoxylin and eosin (H&E) 
staining confirmed that the nodules on the surfaces of 
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Figure 1: ZIPK increases tumor growth and proliferation in vitro and in vivo. (A) XTT assay showed that over-expression of 
ZIPK increased cell proliferation, and ablation of endogenous ZIPK inhibited cell proliferation. The results were expressed as the mean ± 
SD of three independent experiments (**indicates P < 0.01 in independent Student’s t-test). (B) Foci formation assay was used to compare 
the frequency of foci formation between ZIPK- and vector-transfected cells. Quantitative analyses of foci numbers was shown in the right 
panel. Values was reflected as the mean ± SD of at least three independent experiments (***indicates P < 0.001, independent Student’s 
t-test). (C) Ability to form colony in soft agar increased significantly in ZIPK-transfected cells compared with vector cells (**P < 0.01, 
independent Student’s t-test. Scale bars: 100 μm). (D) ZIPK- and empty vector-transfected cells were injected into the left and right dorsal 
area of the nude mice, respectively. ZIPK mediated tumor growth in vivo. The average tumor volume was expressed as the mean ± SD of 
five inoculated sites for each group (***P < 0.001).
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Figure 2: ZIPK promotes cell invasion and gastric cancer metastasis. (A) Wound-healing assay showed that over-expression of 
ZIPK promoted cell migration. Silencing ZIPK inhibited cell migration (Scale bars: 100 μm). Representative images were taken at 0 h, 48 h 
and 72 h after scratching. (B) Transwell assay indicated that over-expression of ZIPK promoted cell migration and invasion. Inversely, 
ZIPK ablation repressed cell migration and invasion (Scale bars: 100 μm). (C) The effects of ZIPK on tumor metastasis in vivo were 
evaluated by tail vein injections of cells in nude mice. Representative images of lungs derived from nude mice injected with ZIPK- or empty 
vector-transfected BGC823 cells were shown in the left panel. Number of visible surface metastatic lesions was indicated in the right panel 
(*indicates P < 0.05, independent Student’s t-test). (D) Lung metastases in the mice were confirmed by H&E staining (Scale bars: 100 μm).
Oncotarget8327www.impactjournals.com/oncotarget
mice lungs were metastatic tumors. Histological analyses 
further revealed that ZIPK promoted metastasis of BGC-
823 cell line (Figure 2D).
ZIPK induces epithelial-mesenchymal transition 
in gastric cancer cells
As shown in Figure 3A, overexpression of ZIPK 
led to altered morphological characteristics of epithelial-
mesenchymal transition (EMT), identified by a scattered 
distribution of cells and spindle or star-like morphology 
of the cells in culture. Since the in vitro and in vivo 
experiments showed that ZIPK could play a pivotal role in 
gastric cancer cell metastasis, we next asked whether ZIPK 
affect on cell biological programs that initiate metastasis 
cascades. EMT has been recognized as a critical event in 
tumor metastasis. To validate whether ZIPK enhances 
gastric cancer metastasis via inducing EMT, the expression 
levels of EMT markers were detected by Western blot 
and qRT-PCR in ZIPK-transfected, ZIPK-silenced and 
their respective control cells. We found that the epithelial 
marker, E-cadherin was dramatically down-regulated in the 
ZIPK-transfected cells, but mesenchymal markers such as 
vimentin and fibronectin were strongly up-regulated in ZIPK 
transfectcted BGC-823 cells. Moreover, overexpression of 
ZIPK increased β-catenin and its nuclear translocation. As 
expected, opposite expression profiles of these proteins were 
detected in ZIPK-silenced cells (Figure 3B, 3C). Increased 
nuclear accumulation of β-catenin is a known transcription 
factor that regulates the activity of TCF/LEF family to 
facilitate EMT and metastasis [13]. Collectively, these data 
suggest that ZIPK might be a positive mediator of EMT and 
metastasis in gastric cancer cells.
ZIPK activates AKT/IκB/NF-kB signaling to 
induce EMT
To further explore the molecular mechanisms 
responsible for ZIPK mediated EMT, we focused on AKT 
signaling because activation of AKT is a central feature 
of EMT and ZIPK has been demonstrated to increase 
AKT activation in spontaneously hypertensive rats [14]. 
We examined the expression levels of phosphorylated 
AKT and AKT by Western blotting. ZIPK-transfected 
BGC823 cells displayed high levels of phosphorylated 
AKT than did empty vector-transfected cells (Figure 4A). 
AKT does not directly regulate gene transcription, but it 
phosphorylates many substrates that activate downstream 
EMT-related gene. GSK-3β has been characterized as a 
main kinase responsible for protein stability of Snail [15]. 
However, in this study, we did not detect any change in 
GSK-3β activity between ZIPK-transfected and vector-
transfected BGC823 cells (Figure 4A). The AKT/IκB 
pathway has also been reported to strongly regulate NF-
κB expression and activation [16]. Moreover, NF-κB 
can modulate EMT phenotype via inducing Snail and 
Slug expression [17, 18]. Therefore, we examined the 
expression of AKT downstream targets, NF-κB, Snail 
and Slug by Western blot analysis. Indeed, we found that 
p-IKKα, p-IκBα, NF-κB, Snail and Slug were significantly 
up-regulated and that IκBα was down-regulated in ZIPK-
transfected cells (Figure 4A). The Slug mRNA levels were 
higher and the Snail mRNA levels were slightly increased 
in the ZIPK-transfected cells (Figure 4B). Knockdown of 
ZIPK dramatically decreased p-IKKα, p-IκBα and NF-
κB expression and increased IκBα level. Silencing ZIPK 
inhibited slug expression in SGC7901 cells and decreased 
both slug and snail expression in SNU-1 cells (Figure 
4A, 4B). These data suggest that ZIPK overexpression 
enhances AKT/IκB/NF-κB signaling. To verify the crucial 
role of AKT signaling pathway in ZIPK induced EMT, 
we treated cells with the specific PI3K/AKT antagonist, 
LY294002. After treating ZIPK-transfected cells with 
LY294002 for 2 h, we examined pAKT, AKT, p-IKKα, 
p-IκBα, IκBα, NF-κB, Snail, and Slug expression. The 
results showed that AKT inactivation dramatically 
suppressed p-IKKα, p-IκBα, NF-κB, Snail and Slug 
expression and restored IκBα expression (Figure 5A). 
In addition, wound healing assay and Transwell assay 
demonstrated that LY294002 could significantly decrease 
cell migration and invasion abilities in ZIPK-transfected 
cells (Figure 5B, 5C). Since PTEN is a major negative 
regulator of the PI3K/AKT signaling pathway, we 
investigated whether ZIPK has a effect on PTEN protein 
stability. Phosphorylation of PTEN (ser380) was detected 
by Western blotting. We found that ZIPK did not seem to 
regulate PTEN stability (Figure 4A).
ZIPK increases stemness of gastric cancer cells
There is emerging evidence that the EMT process 
may give rise to cancer stem cells (CSCs) or cells with 
stem cell-like properties. We further examined if ZIPK 
could increase stemness of gastric cancer cells by 
determining expression levels of stemness-associated 
genes through qRT-PCR. The results showed that 
stemness genes (Nanog and Oct-4), multiple drug-resistant 
transporter gene (ABCG2) and surface antigens associated 
with cancer stem cells (CD24, CD44 and CD133) were 
upregulated in ZIPK-transfected cells compared with 
control cells (Figure 6A). Flow cytometry assay showed 
that the expression level of CD44, CD24 and CD133 was 
high in ZIPK-transfected cells (Figure 6B).
Clinical association of ZIPK expression in 
primary gastric cancers and the matched 
metastatic lymph nodes
The above findings are in contrast with our previous 
study that showed that ZIPK is a tumor suppressor in 
human primary gastric cancers. Of note, BGC-823 and 
SNU-1 cell lines used here have been reported to display 
poor differentiation and aggressive biological behaviors 
[19–21]. Additionally, SGC-7901 cell line originated 
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from metastatic lymph node, so we presumed that the 
oncogenic function of ZIPK would present at late stages 
when it could promote widespread metastases. To validate 
our hypothesis, the expression of ZIPK was examined 
in 79 pairs of primary gastric cancers and their matched 
metastatic lymph nodes by IHC. ZIPK expression could 
be evaluated informatively in 67 of 79 gastric cancers. 
The results showed that high expression of ZIPK was 
Figure 3: ZIPK induces epithelial-mesenchymal transition. (A) Effect of ZIPK over-expression on cell morphology evaluated 
by phase-contrast microscopy (Scale bars: 100 μm). (B) Expression of epithelial cell marker (E-cadherin), mesenchymal cell markers 
(vimentin, fironectin and N-cadherin) and β-catenin were examined by Western blot analysis in ZIPK-overexpressed, ZIPK-silenced and 
their respective control cells. GAPDH was used as a loading control. Intensities of bands were analyzed by the Macintosh densitometry 
program Image J (NIH, Bethesda, MD). (C) Relative expressions of E-cadherin, N-cadherin, vimentin, fibronectin, β-catenin were detected 
by qPCR in ZIPK-overexpressed, ZIPK-silenced and their respective control cells.
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detected in 15/67 (22.4%) primary GCs and 28/67(41.7%) 
metastatic lymph nodes respectively (P = 0.016). In 12 
out of 67 cases, ZIPK was high expressed in both primary 
and metastatic lesions and increased expression of ZIPK 
in metastatic tumors was found in 2 cases (Figure 7A). 
16 cases that expressed ZIPK at low levels in primary 
tumors exhibited high expression only in lymph node 
metastases (Figure 7A). These findings led us to assess 
a possible association between ZIPK expression and 
clinicopathological features in primary tumors and their 
corresponding metastatic lymph nodes. High expression of 
ZIPK in primary or metastatic tumors was not significantly 
associated with age, gender, tumor histological type, 
TNM stage, and organ metastasis (Table 1). Interestingly, 
Figure 4: ZIPK activates AKT/IκBα/NF-κB pathway to induce EMT. (A) Western blot analysis showed the protein levels of 
AKT, pAKT, pPTEN, pGSK3β, IKKα, p-IKKα, IκBα, p-IκBα, p-NF-κB, Snail and Slug in ZIPK-overexpressed, ZIPK-silenced and their 
respective control cells. (B) Relative mRNA expression of Snail and Slug were detected by qPCR in ZIPK-overexpressed, ZIPK-silenced 
and their respective control cells.
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increased expression of ZIPK in lymph node metastases 
as compared to their primary tumors was significantly 
associated with stage IV (P = 0.012) and abdominal organ 
invasion (P = 0.005, Table 1). Furthermore, Kaplan–Meier 
analysis revealed that patients with high ZIPK expression 
in primary tumors had more favorable disease-specific 
survival than those with low ZIPK expression (Log-
rank test, P = 0.03) (Figure 7B). However, patients with 
increased ZIPK expression only in metastatic lymph nodes 
had poor disease-specific survival (Figure 7B). Taken 
together, these results suggest that ZIPK may play a dual 
role in gastric cancer development and progression.
DISCUSSION
Several lines of evidence indicate that ZIPK 
mediates a variety of cell processes including cell death, 
smooth muscle contraction, proliferation, inflammation 
Figure 5: The AKT inhibitor LY294002 decreases ZIPK-induced cell migration and invasion. (A) ZIPK-overexpressed 
cells were treated with LY294002 (20 μM) or DMSO for 2 h, the expressions of pAKT, IKKα, p-IKKα, IκBα, p-IκBα, p-NF-κB, Snail and 
Slug were detected by Western blotting. (B) Wound-healing assay showed that LY294002 strongly inhibited cell migration (**indicates 
P < 0.01, independent Student’s t-test, scale bars: 100). (C) Transwell assay indicated that LY294002 reduced ZIPK-induced cell migration 
and invasion (**indicates P < 0.01, independent Student’s t-test, scale bars: 100).
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and migration [22]. In the past few years, ZIPK has been 
characterized as a tumor suppressor in various tumors. In 
our previous study, ZIPK was down-regulated in 68.9% 
of human primary GCs and low expression of ZIPK was 
significantly associated with invasion, metastasis and 
poorer prognosis [8]. John et al [9]. reported that three 
nonsynonymous point mutations in ZIPK (T112M, 
D161N, and P216S), identified in cancer cells, decreased 
or abolished kinase activity which could abrogate the 
growth inhibitory roles of ZIPK and lead to in vitro cell 
proliferation. However, DAPK family kinases have been 
demonstrated to perform an essential survival function. 
DAPK1 promotes TSC2 phosphorylation resulting 
in TSC1-TSC2 complex dissociation and mTORC1 
signaling activation [11]. ZIPK increases Wnt/β-catenin-
mediated transcription and gene expression through its 
interaction with NLK. Knockdown of ZIPK in human 
colon carcinoma cells induces a reduction of Wnt/β-
catenin signaling and cell growth [23]. Our current study 
showed that patients at stages III–IV with high ZIPK 
Figure 6: ZIPK enhances stemness of gastric cancer cells. (A) Quantitative real-time PCR analysis showed the elevated 
expression of Oct-4, Nanog, ABCG2, CD44, CD24 and CD133 in ZIPK-transfected cells compared with control cells (**indicates  
P < 0.01; ***indicates P < 0.001, independent Student’s t-test). (B) Flow cytometry analysis showed the higher mean flourscence indensity 
of FITC-CD44, PE-CD24, and PE-CD133 in ZIPK-transfected cells (**indicates P < 0.01, independent Student’s t-test).
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Figure 7: The prognostic significance of ZIPK expression in primary GCs and matched metastatic lymph nodes.  
(A) Immunohistochemical analysis of ZIPK expression in primary cancer tissues and matched lymph node metastases (200 × 
magnification, Scale bars: 100). Representative images in the upper panel illustrated that the levels of ZIPK expression were not different 
between primary and metastatic cancers. Images in the lower panel showed increased ZIPK expression in lymph node metastases 
compared to their primary tumors. (B) Kaplan–Meier survival analysis of ZIPK expression in total 67 gastric cancer patients. High 
expression of ZIPK in primary tumors was significantly associated with better disease specific survival rates of GC patients (upper 
left panel); increased ZIPK expression only in metastatic lymph nodes was correlated with poorer disease specific survival (low left 
panel). ZIPK-HE, ZIPK high expression; ZIPK-LE, ZIPK low expression; ZIPK-IE, ZIPK increased expression; ZIPK-NIE, ZIPK non 
increased expression.
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expression in primary tumors had more favorable disease-
specific survival than those with low ZIPK expression. 
This result is in accordance with our previous finding 
from 172 patients at all stages [8]. On the other hand, we 
also found that the frequency of ZIPK high expression was 
increased in metastatic lymph nodes compared to primary 
tumors. Moreover, increased expression of ZIPK in lymph 
node metastases was significantly associated with stage 
IV, abdominal organ invasion and poorer prognosis. 
Furthermore, our functional studies demonstrated that 
ZIPK had strong tumorigenicity, with overexpression of 
ZIPK promoting cell growth, proliferation, migration, 
invasion and tumor formation in nude mice. The role 
of ZIPK in promoting tumor metastasis was further 
validated in nude mouse metastasis models. Based on our 
clinical and experimental observations, we surmise that 
ZIPK functions as a tumor suppressor in primary tumor 
development and as a pro-oncogenic factor to enhance 
distant metastasis. The complex roles in carcinogenesis 
may be due to the involvements of ZIPK in a broad range 
of biological activities. Pro-cell death properties of ZIPK 
could contribute to tumor suppression via increasing 
tumor cell sensitivity to programmed cell death and 
maintaining genomic stability [22, 24, 25]. In the past 
few years, a series of experiments showed that the DAPK 
family trigger the autophagy process and strongly promote 
autophagic cell death [24]. ZIPK is involved in myosin II 
activation and the movement of Atg9-mediated complex 
during starvation-induced autophagy [6]. We have recently 
found that ZIPK inhibits cell proliferation, growth, 
migration and invasion through inducing autophagy in 
Ges-1 and MKN28 cells (unpublished data). In addition, 
ZIPK positively mediates platelet-derived growth factor-
BB-induced vascular smooth muscle cell proliferation 
and migration [22]. Our current data confirm the effects 
of ZIPK on proliferation and migration in BGC-823, 
SGC-7901 and SNU-1 cells. These pro-oncogenic 
capabilities could promote cancer cells from lymph nodes 
Table 1: Clinical association of ZIPK expression in primary gastric cancers and the matched 
metastatic lymph nodes
Variable ZIPK protein
All case High expression in 
primary tumor
P High expression in 
metastatic lymph 
node
P Increased 
expression only 
in metastatic 
lymph node
P
Age (years) 0.377 0.289 0.660
 ≤ 561 29 5 10 7
 > 56 38 10 18 11
Sex
 Female 11 3 0.671 7 0.086 6 0.146
 Male 56 12 21 12
Histological type2 0.118 0.702 0.686
 WA 14 6 6 2
 PA 39 8 18 12
 MA 8 0 2 2
 SRC 6 1 2 2
Stage 0.451 0.098 0.012
 III 39 10 13 6
 IV 28 5 15 12
Organ metastasis 0.524 0.153 0.005
 M0 47 12 17 8
 M1 20 3 11 10
1Mean age
2Histological type: WA, well/moderately differentiated adenocarcinoma; PA, poorly differentiated adenocarcinoma; MA, 
mucinous adenocarcinoma; SRC, signet ring cell carcinoma; UC,undifferentiated
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to disseminate to distant organs. The alternative possibility 
would be that ZIPK plays different roles depending on 
the specific genetic and/or epigenetic alteration that 
occur during tumor progression. Accumulating evidences 
suggest that genetic or epigenetic divergence between 
primary tumor and metastasis results from the clonal 
evolution shaped by microenvironment-specific selection 
forces [26]. Our study have not deciphered the mechanism 
by which ZIPK can switch from a tumor suppressor to a 
pro-metastatic factor during the course of multi-step tumor 
progression. Thus, further investigations will be needed.
Metastasis is a multistep process including local 
invasion, intravasation, transport, extravasation, and 
colonization by which tumor cells disseminate from their 
primary site and form secondary tumors at a distant site. 
This process is essentially dependent on the prominent 
biological event referred to as epithelial-mesenchymal 
transition (EMT) [27, 28]. EMT which enables cells of 
epithelial phenotype to generate mesenchymal derivatives 
can be defined by the loss of cell–cell adhesion, the 
modification of cell morphology and the ability of cells to 
migrate [29–31]. In our study, ZIPK indeed induced EMT 
with increasing expression of β-catenin, mesenchymal 
markers, Snail and Slug. AKT is considered to be a 
key mediator of EMT induction in human epithelial 
malignancies. It is well accepted that AKT induces 
inactivation (phosphorylation) of GSK-3β, subsequently 
phosphorylating Snail, inducing its degradation and 
nuclear export, and ultimately triggering cell EMT 
[15]. Alternatively, AKT can directly phosphorylate 
IKKa, a component of IKK (IκB kinase) complex [16]. 
Phosphorylated IKKa can phosphorylate IκBa, leading 
to its ubiquitination and degradation by the proteasome, 
which can liberate NF-κB to enter the nucleus and up-
regulate Snail and Slug expression to promote EMT [16–
18, 32, 33]. In our study, over-expression of ZIPK induced 
AKT activation, and enhanced phosphorylation of IKKa, 
IkBa and NF-κB, suggesting that ZIPK regulates AKT/
IκB/NF-κB signaling. Slug and snail were up-regulated by 
NF-κB activation, but expression of Slug was dramatically 
elevated in our experiments. A similar finding has also 
been reported in Hec251 cells [18]. Moreover, inhibition 
of AKT activation by LY294002 strongly suppressed 
expression levels of phosphorylated IKKa, phosphorylated 
IkBa, phosphorylated NF-κB, Snail and Slug, and 
prevented ZIPK-induced cell migration and invasion. 
Therefore, ZIPK promotes EMT and tumor metastasis 
through activating the AKT/IκBa/NF-κB signaling 
pathway. Here, we found that ZIPK promoted cell growth, 
proliferation and tumor formation in vivo and in vitro. The 
activation of EMT programs has been associated with 
the acquisition of stem cell traits by various cancer cells 
[34–36]. We detected the effect of ZIPK on stemness-
associated genes and CSC surface markers in ZIPK- and 
empty vector-transfected BGC-823 cells. The results 
indicated that ZIPK could enhance stemness of gastric 
cancer cells. Cancer stem cells display self-renewal 
potential and the ability to initiate new tumors which may 
be of critical importance for colonization in the last step 
of the metastatic cascade [37]. Despite Wnt/β-catenin 
signaling [23], ZIPK-induced AKT activation may play a 
critical role in tumor growth. As mentioned above, ZIPK 
could not only promote cancer cell translocation by EMT, 
but also facilitate metastatic cell growth and colonization 
in distant organs.
Our observations have potential implications for 
gastric cancer treatment. At early stages, restoration 
of ZIPK expression might be effective in preventing or 
delaying subsequent development of gastric cancer, but 
it would be unwise in terminal stage disease because of 
the risk of promoting metastasis. A recent report showed 
that ZIPK modulate inflammatory responses in cultured 
vascular smooth muscle cells through activation of JNK, 
p38, and AKT, as well as reactive oxygen species (ROS) 
production. Using a DAPK inhibitor could prevent 
activation of AKT and hypertrophy in isolated mesenteric 
arteries via suppressing cell proliferation in spontaneously 
hypertensive rats [14]. Thus, DAPK inhibiter may be a 
promising agent for the therapy of terminal gastric cancer. 
Recent advances in our understanding of transforming 
growth factor (TGF)-β in tumor progression have 
indicated that it acts as a tumor suppressor early and as 
a pro-metastatic factor in late-stages. Administration of 
anti-TGF-β therapies for metastatic cancers has brought 
promising results in the preclinical and clinical settings 
[38, 39]. These successes will provide substantial evidence 
to improve personalized cancer therapy in the future.
In summary, our studies have found that over-
expression of ZIPK promotes cell growth, invasion, 
tumor formation and metastasis. ZIPK enhances AKT 
activity and induces EMT through AKT-IκBa-NF-κB 
signaling. Increased expression of ZIPK in human lymph 
node metastases is significantly associated with stage 
IV, abdominal organ invasion and poor prognosis of GC 
patients. These findings reveal that ZIPK may serve as 
a pro-oncogenic factor for cancer cell translocation and 
colonization in distant organs.
MATERIALS AND METHODS
Clinical samples and cell lines
Paired tumor and metastatic lymph node specimens 
of 79 gastric cancer patients, who underwent gastrectomy 
between 2001 and 2003, were obtained from archives of the 
Department of Pathology of the First Affiliated Hospital, 
Sun Yat-sen University (Guangzhou, China). The patients 
included 66 males and 13 females, ranging in age from 27 
to 84 years. Tumor histological types and differentiation 
were determined based on World Health Organization and 
Japanese Research Society for GC criteria [40, 41]. Tumor 
staging was defined according to the tumor-node-metastasis 
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(TNM) classification system from International Union 
Against Cancer (UICC) recommendation [42]. All patients 
received chemotherapy (fluorouracil, mitomycin, and 
adriamycin) after gastrectomy and were followed up. Clinical 
and pathological features of these patients were summarized 
in Supplementary Table 1. All human tissues were obtained 
with informed consent and approval from the Committees for 
Ethical Review of Research in the First Affiliated Hospital, 
Sun Yat-Sen University. BGC-823, SNU-1 and SGC-7901 
cell lines was kindly provided by Professor Jie Chen from the 
Department of Gastroenterology, the First Affiliated Hospital 
of Sun Yat-sen University. RPMI-1640 medium with 10% 
fetal bovine serum was used in culture.
Establishment of ZIPK overexpressed cell lines
The ZIPK gene expression vector (EX-M0353-
Lv130) and the vector control (EX-NEG-Lv130) were 
obtained from GeneCopoeia (GeneCopoeia, MD). To 
produce infectious lentiviral particles, 293FT cells 
cultured on 10 cm dishes were cotransfected with target 
plasmids and the packaging plasmids in the Lenti-
Pac HIV packaging mix (GeneCopoeia, MD). Viral 
supernatants were harvested after 2 day transfection, and 
then these supernatants were added in BGC823 culture. 
After infection, cells were selected in 3 μg/ml puromycin 
for 2 weeks.
RNA interference
Small interfering RNA (siRNA) (50 pM) against 
ZIPK (Genepharma, Shanghai) was transfected into 
SGC-7901 and SNU-1 cells in 6-well plates using 
Lipofectamine 2000 Reagent (Invitrogen, NY) according 
to the manufacturer’s instructions. At 48 hours after 
transfection, the effects of gene silencing were measured 
via western blot analysis, XTT, wound healing and 
Transwell. The siRNAs targeting ZIPK were as follows: 
ZIPK-1,5′-CUGGAACAUUCCUGGAUUAT-3′;ZIPK-
2,5′GGAACGAGUU-CAAGAACAUTT-3′;ZIPK-3,5′-
GCAUCGCACACUUUGACCUTT-3′. Control siRNA 
was obtained from Genepharma (nonsi lencing, catalog 
No.141201).
Quantitative reverse transcription-PCR
Total RNA was extracted from cultured cells using 
TRIzol® reagent (Invitrogen, NY). Single-stranded cDNA 
was generated from total RNA, using M-MLV reverse 
transcriptase and oligo (dT) 12–18 primers (Takara, 
Japan). The real-time quantitative PCR reaction was 
performed with the SYBR green detection system (Bio 
SYBR Green Master Mix, Takara, Japan). GAPDH served 
as an endogenous control. All cycle threshold (ct) values 
were determined in real time using CFX96™ Real-Time 
PCR Detection (Bio-rad, CA). The primer pairs for each 
target gene is listed in Supplementary Table 2.
Immunoblot analysis
Total cellular and nuclear proteins were extracted 
from 70–80% confluent cultured cells, and separated 
using standard SDS–PAGE and transferred onto PVDF 
membranes. Membranes were probed with different 
optimally diluted primary antibodies, followed by a 
colorimetric method for immunosignal visualization. 
Rabbit anti-ZIPK antibody was purchased from ProSci 
Incorporated (Prosci, Poway, CA). Anti-E-cadherin, 
-N-cadherin,-β-catenin,-Vimentin, -Snail, and -Slug 
antibodies were purchased as part of the EMT Antibody 
Sampler Kit (Cell Signalling Technology, MA). Rabbit 
anti-AKT, -p-AKT, -p-PTEN, and -p-GSK-3β antibodies 
were purchased as part of the Phospho-AKT Pathway 
Antibody Sampler Kit (Cell Signalling Technology, 
MA). Rabbit anti-IKKα,-p-IKKα,-IκBα,-p-IκBα,-NF-κB, 
and -p-NF-κB antibodies were purchased as part of the 
Phospho-NF-kB Pathway Antibody Sampler Kit (Cell 
Signalling Technology, MA).
In vitro tumorigenic assays
Foci formation assay, and soft agar assay were 
performed as described previously [43]. For foci 
formation assay, 1 × 102 cells were plated in separate 
wells of a 6-cm2 plate. Surviving colonies (> 50 cells 
per colony) were stained with crystal violet and counted 
after 3 weeks of culture. For soft agar assay, 5 × 103 
cells were grown in 0.4% bactoagar on a bottom layer of 
solidified 0.6% bactoagar in 6-cm2 plates. After 3 weeks, 
colonies consisted of more than 80 cells were counted. 
All data were expressed as the means ± S.E.M. Triplicate 
independent experiments were performed for each assay. 
For cell growth assay, 5 × 102 BGC-823, 1 × 103 SGC-
7901 and 1 × 103 SNU-1 cells were seeded into 96-well 
plate respectively and cell growth rate was detected using 
cell proliferation XTT kit (Dojindo, Japan) according to 
the manufacturer’s instructions.
In vivo tumor formation assays
Animal experiments were performed in compliance 
with the guidelines for the Welfare of Experimental 
Animals in Sun Yat-sen University. For in vivo 
tumorigenicity assay, 5 × 105 ZIPK- and empty vector- 
transfected cells were subcutaneously injected into the 
left and right dorsal flank, respectively, of 4- to 5-week 
old nude mice (five mice per group). Tumor volume was 
measured weekly over a 4-week period (formula: Volume 
= 0.5 × Length × 2 × Width).
In vitro migration and invasion assays
ZIPK-transfected, ZIPK-silenced and their 
respective control cells were cultured on 35 mm dish 
until confluent, then wounded with a 10 μl pipette tip. 
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Migration photos were captured at 0 hr, 24 hr and 48 
hr after scratching. Transwell invasion assay was per-
formed using polyethylene terephthalate-based migration 
chambers and BD BioCoat Matrigel Invasion Chambers 
(Becton Dickinson Labware, USA) according to the 
manufacturer’s instructions. The number of invades cells 
was quantified in 10 fields under a 10 × objective lens.
In vivo metastasis assay
Briefly, 5 × 105 cells transfected with empty vector or 
ZIPK were intravenously injected through the tail vein of 
4- to 5-week-old nude mice (five mice per group). After 8 
weeks, the mice were euthanized and the number of surface 
metastases per lung was determined under a dissecting 
microscope. The lungs were excised and embedded in 
paraffin, where by hematoxylin and eosin (H&E) staining 
was performed to confirm the presence of tumors.
Flow cytometry
ZIPK-overexpressed and control cells were 
trypsinized, washed twice with PBS and immunostained 
for 30 min on ice with monoclonal antibodies against 
CD24 (PE-conjugated, BD Bosciences, CA), CD133 (PE-
conjugated, Miltenyi Biotec, GMBH) and CD44 (FITC-
conjugated, BD Bosciences, CA,). Labeled cells were 
analyzed using a flow cytometer (FACS Calibur, Becton 
Dickinson). Background signals were established using 
control cells incubated with isotype-specific IgGs.
Tissue microarray and immunohistochemistry
The tissue microarray (TMA) blocks were 
constructed according to a previously described method 
[8]. Staining was performed on 5-μm paraffin sections. 
Sections were deparaffinized in xylenes and graded 
ethanol, and then rehydrated in PBS. Antigen retrieval was 
performed by microwaving for 10 min in 10 mM citrate 
buffer (pH 6.0). Endogenous peroxidase activity was 
blocked with 3% hydrogen peroxide for 20 min. The TMA 
sections were incubated with rabbit polyclonal antibody 
against ZIPK (Prosci, Poway, CA) at a dilution of 1:100 
overnight at 4°C. After incubation with peroxidase–linked 
secondary antibody (Envision detection system, Dako, 
Glostrup, Denmark), TMA sections were counterstained 
with Mayer’s hematoxylin.
Immunostaining of ZIPK was evaluated by a semi-
quantitative scoring system, described previously [8]. 
Cytoplasmic expression of ZIPK with staining index ≥ 4 was
defined as high expression and cytoplasmic expression 
of ZIPK with staining index < 4 was defined as low 
expression in the present study. Lost, unrepresentative 
samples, and samples with too few tumor cells (< 100 
cells) were excluded from the data analysis. All IHC 
results were evaluated by 2 independent pathologists 
without any prior knowledge of the clinicopathologic data. 
With discrepant results of the same slide, both observers 
reviewed again to obtain a consensus.
Statistical analysis
Statistical analysis was conducted using SPSS 
version 13.0 (Chicago, IL). Student’s t-test was performed 
to evaluate the data from cell growth, foci formation, 
soft agar assays, tumor formation and metastasis in nude 
mice, wound healing, transwell, Western blot and qPCR 
assays. Chi-square test was used to analyze the correlation 
between ZIPK expression and clinicopathological 
variables. Cancer specific survival rates were estimated 
by Kaplan–Meier analysis. The value of P < 0.05 was 
considered statistically significant.
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